Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.

ABSTRACT:

Objective

To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).

Methods

In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis, respectively. This post hoc analysis evaluated associations between W24 DR or ER and W48 achievement of stringent disease control measures using logistic regression.

Results

At baseline, 103/285 (36.1%) patients had

SUBMITTER: Marzo-Ortega H 

PROVIDER: S-EPMC12862382 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature